Lawsuits Grow Over GLP-1 Drugs and Rare Vision Loss

Hundreds of lawsuits are targeting GLP-1 drugs such as Wegovy, Ozempic, and Mounjaro after reports of sudden vision loss due to NAION, a rare optic nerve condition. While doctors say the overall risk appears very small and the drugs’ benefits often outweigh potential harms, labels already warn of vision changes and regulators, including the FDA, are monitoring safety. Experts note the evidence is mixed on increased NAION risk, but victims like Diane Wirth allege inadequate warnings, prompting calls for updated labeling and continued vigilance.